Holen Sie sich die Stockscreener-App
1.10
2.65%
-0.03
Schlusskurs vom Vortag:
$1.13
Offen:
$1.14
24-Stunden-Volumen:
361.23K
Relative Volume:
0.77
Marktkapitalisierung:
$64.06M
Einnahmen:
$54.77M
Nettoeinkommen (Verlust:
$15.24M
KGV:
4.5156
EPS:
0.2436
Netto-Cashflow:
$7.24M
1W Leistung:
-8.33%
1M Leistung:
-0.90%
6M Leistung:
-58.96%
1J Leistung:
-53.19%
1-Tages-Spanne:
$1.09
$1.17
1-Wochen-Bereich:
$1.09
$1.22
52-Wochen-Spanne:
$1.08
$3.08
Spero Therapeutics Inc Stock (SPRO) Company Profile
Firmenname
Spero Therapeutics Inc
Sektor
Branche
Telefon
857-242-1600
Adresse
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
1.10 | 64.06M | 54.77M | 15.24M | 7.24M | 0.2436 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-09-23 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-10-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2021-01-22 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-09-29 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-09-09 | Eingeleitet | Janney | Buy |
| 2018-02-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-27 | Eingeleitet | BofA/Merrill | Neutral |
| 2017-11-27 | Eingeleitet | Oppenheimer | Outperform |
| 2017-11-27 | Eingeleitet | Stifel | Buy |
Alle ansehen
Spero Therapeutics Inc Aktie (SPRO) Neueste Nachrichten
Spero Therapeutics grants 556,000 awards to new hires for Spero Therapeutics stock - ad-hoc-news.de
Complicated Urinary Tract Infections Market Set for Expansion by 2036, Supported by Recent Drug Approvals Including GSK/Spero Therapeutics’ UTEBZI and Wockhardt’s ZAYNICH and Emerging Therapies | DelveInsight - GlobeNewswire Inc.
Discover Spero Therapeutics Alongside Two Promising Penny Stocks - simplywall.st
Spero Therapeutics (NasdaqGS:SPRO) Stock Forecast & Analyst Predictions - Simply Wall Street
SPROSpero Therapeutics Inc Short Interest - Finviz
Spero Therapeutics, Inc. SEC Filing (Sep 11, 2026) - Stock Titan
Spero Therapeutics (SPRO) 10K Form and Latest SEC Filings 2026 - marketbeat.com
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New employees get stock awards at Spero, unlocking from 2027 - Stock Titan
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - marketscreener.com
A biotech CEO will speak in New York Sept. 15. Spero will stream it. - Stock Titan
Spero Therapeutics stock gains on small-cap biotech interest - ad-hoc-news.de
Resilient Spero Therapeutics stock prepares up to $300 million shelf as Nasdaq price holds around $1 - ad-hoc-news.de
Spero Therapeutics Launches New ATM Program With Jefferies for Up to $100 Million - TradingView
Spero TherapeuticsMay Offer Up To $300 Million In SecuritiesSEC Filing - tradingview.com
Spero Therapeutics Inc. (SPRO) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Spero Therapeutics Inc. (SPRO) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Spero Therapeutics Company Profile & Introduction - Moomoo
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript - AOL.com
Alphabet Inc. Makes New Investment in Spero Therapeutics, Inc. $SPRO - MarketBeat
Spero Therapeutics, Inc.: Shareholders Board Members Managers and Company Profile | US84833T1034 - marketscreener.com
Diluted shares outstanding of Spero Therapeutics, Inc. – BIVA:SPRO - TradingView
Long term debt to total assets ratio of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Net current asset value per share of Spero Therapeutics, Inc. – BMV:SPRO - TradingView
Spero Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ... - Yahoo Finance
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights - GuruFocus
SPRO Looks 14.8% Overvalued on GF Value™ as FDA Approval Spurs I - GuruFocus
Spero Therapeutics Q2 Earnings Call Highlights - MarketBeat
Spero Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
SPRO: FDA approval, immunology pivot, and $105M financing extend cash runway into 2029 - TradingView
Earnings call transcript: Spero Therapeutics posts small q2 2026 EPS beat - Investing.com
Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Is Spero Therapeutics Inc (SPRO) a Smart Investment Post Q2 Earnings? GF Score: 69/100, 13.3% Overvalued - GuruFocus
SPRO: FDA approval of Utebzi and $105M financing position the company for long-term growth - tradingview.com
Spero Therapeutics 2Q 2026: Revenue $0M, EPS $(0.16) — 10-Q Summary - TradingView
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update - The Manila Times
Spero Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Spero Therapeutics (SPRO) Slips to $1.26: Stock Holds Tight Range Between $1.20 Support and $1.32 ResistanceThematic ETF Flow - vinanet.vn
Spero Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Equity awards for Spero Therapeutics (SPRO) chief medical officer - Stock Titan
Spero Therapeutics CMO Debra Zack files initial beneficial ownership statement - Bitget
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
SPRO Q2'26 Earnings: EPS estimate is (0.17) USD - TradingView
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - The Manila Times
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - marketscreener.com
Finanzdaten der Spero Therapeutics Inc-Aktie (SPRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Spero Therapeutics Inc-Aktie (SPRO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keutzer Timothy | Chief Operating Officer |
Feb 06 '26 |
Sale |
2.36 |
18,652 |
44,019 |
742,506 |
| Rajavelu Esther | See Remarks |
Feb 06 '26 |
Sale |
2.36 |
87,917 |
207,484 |
1,012,091 |
| Keutzer Timothy | Chief Operating Officer |
Feb 04 '26 |
Sale |
2.24 |
3,471 |
7,775 |
761,158 |
| Keutzer Timothy | Chief Operating Officer |
Feb 03 '26 |
Sale |
2.14 |
24,224 |
51,839 |
764,629 |
| Keutzer Timothy | Chief Operating Officer |
Feb 02 '26 |
Sale |
2.20 |
18,891 |
41,560 |
788,853 |
| Rajavelu Esther | See Remarks |
Feb 02 '26 |
Sale |
2.20 |
18,442 |
40,572 |
1,100,008 |
| Rajavelu Esther | See Remarks |
Nov 07 '25 |
Sale |
2.37 |
40,270 |
95,440 |
869,450 |
4.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):